First, since the retrospective design nature of our study, some indicators, including HBV genotype, HBeAg titer, liver fibrosis stage, treatment experience with prior IFN or NUCs, will inevitably be missing, and this study is biased to a certain extent. This evidence concerns the gene IFNA1 and Hepatic fibrosis.